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Abstract: The objective of this study was to examine the cost-
effectiveness of angiotensin-converting enzyme inhibitor (ACEI)-based
treatment compared with thiazide diuretic-based treatment for hyper-
tension in elderly Australians considering diabetes as an outcome along
with cardiovascular outcomes from the Australian government’s
perspective.
We used a cost–utility analysis to estimate the incremental cost-
effectiveness ratio (ICER) per quality-adjusted life-year (QALY)
gained. Data on cardiovascular events and new onset of diabetes were
used from the Second Australian National Blood Pressure Study, a
randomized clinical trial comparing diuretic-based (hydrochlorothia-
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(n¼ 5642); group B was restricted to participants with preexisting
diabetes mellitus (type 1 or type 2) at baseline (n¼ 441). Data on utility
scores for different events were used from available published litera-
tures; whereas, treatment and adverse event management costs were
calculated from direct health care costs available from Australian
government reimbursement data. Costs and QALYs were discounted
at 5% per annum. One-way and probabilistic sensitivity analyses were
performed to assess the uncertainty around utilities and cost data.
After a treatment period of 5 years, for group A, the ICER was
Australian dollars (AUD) 27,698 (s 18,004; AUD 1–s 0.65) per
QALY gained comparing ACEI-based treatment with diuretic-based
treatment (sensitive to the utility value for new-onset diabetes). In group
B, ACEI-based treatment was a dominant strategy (both more effective
and cost-saving). On probabilistic sensitivity analysis, the ICERs per
QALY gained were always below AUD 50,000 for group B; whereas for
group A, the probability of being below AUD 50,000 was 85%.
Although the dispensed price of diuretic-based treatment of hyper-
tension in the elderly is lower, upon considering the potential enhanced
likelihood of the development of diabetes in addition to the costs of
treating cardiovascular disease, ACEI-based treatment may be a more
cost-effective strategy in this population.
(Medicine 94(9):e590)
Abbreviations: ANBP2 = Second Australian National Blood
Pressure, ICER = incremental cost-effectiveness ratio, QALY =
quality-adjusted life-year.
INTRODUCTION
H ypertension or high blood pressure (BP) is a major riskfactor for cardiovascular diseases such as stroke or cor-
onary heart disease.1 The incidence and prevalence of hyper-
tension increases with age.2,3 Worldwide >60% of those aged
65 years and older are hypertensive.4 Evidence suggests that
diabetes and hypertension often coexist, substantially increas-
ing the risk of cardiovascular disease and all-cause mortality.5,6
According to recent Australian data, the prevalence of hyper-
tension in people aged 65 years and older was 70% and of
diabetes 14%.7,8 Management and treatment of these conditions
pose a large burden on the health care system. This burden is
expected to increase due to an ageing society and increasing
levels of obesity and other comorbidities. In 2010, the estimated
cost related to managing hypertension in the United States was
about US$ 93 billion.9 In Australia, antihypertensive drugs
constituted 9.5% of the total annual drug expenditure
for 2011–2012 (Australian dollar [AUD] 9.2 billion) under
the Australian Pharmaceutical Benefits Scheme (PBS).10
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Therefore, understanding and determining the financial impact
of the treatment of hypertension and diabetes is of major
importance for planning health care expenditure.
Lowering of high BP is one of the effective ways to reduce
the incidence of subsequent cardiovascular events; evidence
shows that there are no major differences in BP lowering
between different antihypertensive drug classes as mono-
therapy.11 In addition, the BP Lowering Treatment Trialist’s
Collaboration has shown that there are no differences in
cardiovascular outcomes associated with treating hypertension
using regimens based on different classes of antihypertensive
drugs.12 The current European Society of Hypertension man-
agement guideline recommends in people aged 65 years and
older the initial use of a BP lowering drug from any one of the
following classes: thiazide-type diuretics (thiazide diuretics),
angiotensin-converting enzyme inhibitors (ACEIs), calcium
channel antagonists, or angiotensin receptor antagonists,
depending on other compelling and comorbid conditions in
the individual patient.13 In contrast, the recent hypertension
management guideline of the American Society of Hyperten-
sion and the International Society of Hypertension recommends
the use of either calcium channel antagonists or thiazide diure-
tics as an initial treatment in people aged 60 years and older.14
Among the different antihypertensive drug classes, a thia-
zide diuretic has been claimed to be the preferred first-line and
most cost-effective antihypertensive drug if not otherwise
contraindicated.15,16 However, despite their cost-effectiveness,
thiazide diuretics are not recommended as first-line therapy in
younger hypertensive patients, as their long-term use is associ-
ated with an increased incidence of new-onset diabetes com-
pared with some other commonly used drugs such as ACEIs,
angiotensin receptor antagonists, and calcium channel
antagonists.17,18 Recently, thiazide diuretic-based treatment
regimens have also been shown to be associated with an
increased incidence of new-onset diabetes in treated elderly
hypertensive patients compared with ACEI-based treat-
ments.19,20 Therefore, to assess the cost-effectiveness of hyper-
tension treatment in clinical practice, in addition to the BP
lowering effect and drug dispensing price, the metabolic
changes caused by long-term use of drug therapy need to be
considered. Studies conducted to evaluate the cost-effectiveness
of ACEI-based treatments over thiazide diuretic-based treat-
ments in a general population have demonstrated that diuretic-
based treatment is more cost-effective,21,22 but there is limited
information on the comparative cost-effectiveness of ACEI-
based versus diuretic-based treatment of hypertension in an
elderly population with diabetes as an outcome event in addition
to cardiovascular disease or as a comorbid condition, which is
highly prevalent in elderly hypertensive patients. It is therefore
important to compare the cost-effectiveness of ACEI-based
treatment with diuretic-based treatment of hypertension con-
sidering diabetes as a comorbid condition.
The aim of our study was to determine the cost-effective-
ness of ACEI-based treatment compared with thiazide diuretic-
based treatment in the Australian context, using data from the
Second Australian National BP (ANBP2) study, which was
carried out in elderly hypertensive patients irrespective of
whether diabetes was a comorbid condition.
METHODS
Chowdhury et alStudy Participants and Setting
The ANBP2 study was a prospective randomized open
label blinded endpoint study. Six-thousand eighty-three
2 | www.md-journal.comhypertensive patients aged between 65 and 84 years were
enrolled through 1594 family medical practices throughout
Australia and then randomized to receive either ACEI (mainly
enalapril, n¼ 3044) or thiazide diuretic (mainly hydrochlor-
othiazide, n¼ 3039) based BP-lowering treatment. Among the
inclusion criteria were an average untreated sitting BP at the 2
‘‘study entry’’ visits of 160mm Hg systolic and/or 90mm
Hg diastolic (if systolic was 140mm Hg), having no cardio-
vascular morbidity within 6 months, and willingness to give
informed consent. Exclusion criteria included any life-threaten-
ing illness, contraindication to an ACEI or a thiazide diuretic,
serum creatinine concentration >2.5mg/dL (>221mmol/L),
malignant hypertension, or dementia.
Interventions
Subjects were centrally randomized to either ACEI- or
diuretic-based treatment. The ACEI, enalapril, and the diuretic,
hydrochlorothiazide, were recommended as initial therapy;
however, choice of the specific agent and dose was determined
by the subject’s family practitioner. The study subjects were
followed for a median 4.1 years. During this follow-up period,
detailed information on each subject’s BP, medication use,
relevant laboratory values (eg, plasma cholesterol, serum crea-
tinine, blood glucose), and cardiovascular morbidity and
mortality were collected through follow-up visits. These visits
were conducted on average every 6 months. The study focused
on the clarification and differentiation of the effects of anti-
hypertensive treatment on the incidence of cardiovascular
events. Key findings from the ANBP2 study have been pub-
lished previously.23 The ANBP2 study was approved by the
Ethics Committee of the Royal Australian College of General
Practitioners and conducted according to the Helsinki Declara-
tion of the World Medical Association.
Economic Analysis
We carried out a cost–utility analysis using patient-level
data collected as part of the ANBP2 study to compare the 2
strategies: thiazide diuretic-based and ACEI-based treatments
of hypertension. The perspective of the Australian government
was taken into account while analyzing the data. The outcome
of interest was the incremental cost-effectiveness ratio (ICER)
in terms of AUD per quality-adjusted life-year (QALY) gained.
The ANBP2 study provides real-life data on cardiovascular
adverse events and new-onset diabetes in the elderly treated
hypertensive population for the economic analysis. The
decision model used for the economic analysis is illustrated
in Figure 1. All costs are given in AUD (AUD 1–s 0.65). The
total patient population was stratified into 2 groups based on the
presence of diabetes at baseline (randomization): group A
participants were free from diabetes at baseline (n¼ 5642)
and group B participants were known to have preexisting
diabetes mellitus (type 1 or type 2) at baseline (n¼ 441). Both
groups were followed on-treatment after being randomized for a
median 4.1 years (maximum 5 years) until death or closeout of
the study.
Health Outcomes
Individual information on any cardiovascular events (non-
fatal events and deaths) was collected by study nurses from the
family practice case records during 6-monthly follow-up visits
Medicine  Volume 94, Number 9, March 2015and from hospital notes and death certificates. All information
was then reviewed for end point documentation and adjudicated
for all potential study end points throughout the trial by an end
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FIGURE 1. Outline of the decision model for the cost-effectiveness analysis of ACEI-based treatment versus diuretic-based treatment of
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following events (if experienced) for a participant in the ANBP2
study to calculate the utility values at the end of each year and
associated costs (inpatient hospital costs of complication man-
agement). These events were nonfatal myocardial infarction
(MI), nonfatal stroke, nonfatal heart failure (HF) hospitaliz-
ation, and death from any cause. For group A, in addition to
above events, ‘‘new-onset diabetes’’ was considered as an
additional event (if developed). Overall during the ANBP2 trial
period an incidence rate of 1.45% per annum for diabetes was
observed.18 The ‘‘new-onset diabetes’’ event was based on
observed new development of diabetes during the follow-up
period, defined as the participant being diagnosed or treated
for diabetes by their family practitioner, or first incidence
of a random plasma glucose concentration 11.1mmol/L
(200mg/dL).
Resource Use and Unit Costs (in AUDs)
The Australian government subsidizes family physician
(GP) and specialist consultations (through Medicare Australia),
and the costs of many prescribed pharmaceuticals (under the
Australian PBS) together with funding public hospital care
jointly with the individual states. Patient copayments were
not considered in the current analysis. Moreover, indirect costs
(ie, productivity costs) were not included in the analysis as these
patients were all 65 years, and so relatively few were still
undertaking paid work. The cost parameters used for this
analysis are shown in Table 1. Prices were updated to reflect
recent values.
Pharmaceutical Use and Related Costs
In ANBP2, GPs were responsible for prescribing the drugs
and their doses for treating hypertension in the participants
enrolled in the study. At the time of either prescribing or
dispensing of the medication by a pharmacist, substitution of a
different product from the assigned drug class may have been
provided to the patient, and also there were a variety of doses of
each drug within a recommended dosage range. Therefore,
hypertension in an elderly population. ACEI¼ angiotensin-conve
Pressure, Group A¼hypertensive patients without preexisting d
quality-adjusted life-year.we used estimated drug costs for each antihypertensive
drug class by calculating the sum of each drug dose and its
proportional contribution within the PBS for the drug class.30 The
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.pharmaceutical costs were derived from the PBS reimbursement
data for the calendar year 2012 (January to December).24 For
costing antidiabetic therapy, we used the proportion of patients
treated with diet alone, oral therapy alone, insulin alone, or both
insulin and oral therapies based on estimates derived from the
AusDiab data29,31 and also the cost of routine diagnostic testing
(ie, home glucose strip, 1 pathology test per year, 1 Haemoglobin
A1c test quarterly).
General Practice Visits and Related Costs
In ANBP2, the number of GP consultations for each
participant was recorded, but not the type and duration of
consultation. Both the latter can affect the amount of reimbur-
sement to the treating doctor. The cost of each GP visit was
based on the Australian Medicare Benefit Schedule for the 2012
calendar year.26 The cost (100% schedule fee) for a standard
consultation with a GP in a primary care setting was AUD
36.30. However, the schedule fee can vary from AUD 16.60 to
AUD 106.75 depending on the type and duration of consul-
tation. Therefore, a weighted average of the schedule fees for
GP services for people aged 65 years or older was used.
Costs of Inpatient Complication Management
The costs of inpatient management of nonfatal MI, non-
fatal stroke, nonfatal HF, and fatal events (deaths) were derived
from published data for the relevant Australian Refined Diag-
nosis-Related Groups (AR-DRGs) for public sector hospitals.25
Each AR-DRG represents a class of patients with similar
clinical conditions requiring similar hospital services con-
structed using information in the hospital morbidity record.
Australian national cost weight data were used for each DRG
and adjusted for high outliers with regard to the length of stay.
We calculated a weighted mean cost for each clinical event. As
these derived costs represent the event management cost for the
year 2009, we used the Australian total health price index to
estimate the 2012 values.32
Utilities
g enzyme inhibitor, ANBP2¼Second Australian National Blood
tes at start, ICER¼ incremental cost-effectiveness ratio, QALY¼Utility values range from 0 to 1 and are commonly used in
health economics to reflect an individual’s preferences for
different health outcomes and to measure QALYs. The ‘‘0’’
www.md-journal.com | 3
TABLE 1. Key Input Data: Costs and Health State Utilities
Variables
Base Case (Range for 1-Way
Sensitivity Analysis)
Uncertainty Ranges
(for Probabilistic Sensitivity Analysis) Source
Costs (AUD, Australian government perspective)
Medication cost (annual cost/person)
ACEI 191 Not varied 24
Diuretics 74 Not varied 24
Diabetes management 487 Not varied 24
Cost of complication management (once off/person)
Nonfatal MI 8177 25% (uniform) 25
Nonfatal stroke 12818 25% (uniform) 25
Nonfatal HF hospitalization 7789 25% (uniform) 25
Fatal event (death from any cause)

1754 25% (uniform) Assumption
General practice visit cost/person 41 25% (uniform) 26
Health state utilities
Hypertension (on treatment) 1.00 Not varied Assumption
Diabetes (baseline) 0.86 (0.80–0.95) Not varied Assumption
Nonfatal MI 0.76 (0.50–0.87) Beta distribution 27,28
Nonfatal stroke 0.63 (0.26–0.92) Beta distribution 27,28
Nonfatal HF hospitalization 0.71 (0.43–0.84) Beta distribution 27,28
New-onset diabetes 0.73 (0.60–0.98) Beta distribution 29
Discount rate 5% (3% as an alternative) Not varied
ACEI¼ angiotensin-converting enzyme inhibitor, AUD¼Australian dollar, HF¼ heart failure, MI¼myocardial infarction.
UD
Chowdhury et al Medicine  Volume 94, Number 9, March 2015utility score reflects states of health equivalent to death, whereas
‘‘1’’ reflects perfect health. We have used utility values for
nonfatal MI, stroke, hospitalization for HF, and new-onset
diabetes from published sources (Table 1).27,29,33 In the present
analysis, hypertensive patients without diabetes were con-
sidered to have a utility value of ‘‘1’’ at baseline. We used this
value assuming that there were no significant differences as all
patients were hypertensive and randomized to receive treat-
ment. For group A, we used this value for all participants at the
start. For group B, the utility value of participants with pre-
existing diabetes at baseline was assumed to be 0.86 considering
the selective inclusion criteria of the ANBP2 study participants.
At any time during the follow-up period, if a participant
experienced 2 or more events, the utility value was obtained
by multiplying individual event utilities.28
Incremental Cost-Effectiveness Analysis
We conducted the cost-effectiveness analyses for a repre-
sentative 1000 subjects (simulated) at commencement and
calculated the corresponding events, QALYs and costs for each
year based on observed event rates for ANBP2 participants in
each treatment group following enrolment. An annual discount
rate of 5% was applied to both costs and outcomes.34 The ICER
was calculated as the difference in cost divided by the difference
in QALYs between the treatment groups for a maximum 5 years
of follow-up using the formula: ICER¼ (Cost ACEI-based
treatmentCost diuretic-based treatment)/(QALY ACEI
QALY thiazide diuretics). The Australian government has
not revealed any threshold value for cost-effectiveness in fund-
ing new drugs or treatments for subsidy. However, several

Actual cost for management of fatal event (death) if hospitalized is A
used 50% of the cost for all fatal events.studies have claimed a relationship between the value of
the ICER and the probability of being listed for subsidy.35,36
Based on their findings, as a rough guide, we have used a
4 | www.md-journal.comcost-effectiveness threshold of less than AUD 50,000 per QALY
gained as being cost-effective.
Sensitivity Analyses
We conducted 1-way sensitivity analyses by, in turn,
changing the utility parameter through the ranges listed in
Table 1 and with the cost of complication management
increased/reduced by 20%. We also did a 1-way sensitivity
analysis using a 3% discount rate. The purpose of this was to
assess the credible range for the ICER per QALY gained for
ACEI compared with diuretic-based therapy.We also conducted
1-way sensitivity analysis by varying all outcome utilities or all
costs of adverse outcomes together at their upper and lower
limits of their respective ranges. In addition, to enable a direct
comparison with previous studies, a further sensitivity analysis
was conducted across all trial participants disregarding both
preexisting diabetes at baseline and new-onset diabetes during
follow-up, and the costs of diabetes management during follow-
up. Separate probabilistic sensitivity analyses of groups A and B
were also undertaken via Monte Carlo simulation with 5000
iterations. In these sensitivity analyses, related costs of interest
were entered within 25% uniform uncertainty ranges; utility
values were entered with beta distributions; costs of treatment
and GP visits were used as fixed parameters (Table 1). Results of
these analyses were presented using cost-effectiveness accept-
ability curves. @RISK version 6.2 (Palisade Corporation,
Ithaca, NY) was used for the probabilistic sensitivity analyses.
In addition, Stata version 11.2 for Windows (StataCorp LP,
College Station, TX) and Microsoft Excel (Microsoft Corpor-
ation, Redmond, WA) were used for the economic analysis.
3508.25 Because not all patients were hospitalized for fatal events, weRESULTS
As reported previously, the mean (SD) age of the 6083
ANBP2 subjects at baseline was 72(5) years, and 49% were
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 2. Baseline Characteristics of the Participants by Treatment Group and Presence of Diabetes
Overall




Total ACEI Diuretics ACEI Diuretics ACEI Diuretics
Number 6083 3044 3039 2815 2827 229 212
Age (meanSD, y) 71.9 4.9 72.0 4.9 71.9 5.0 72.0 4.9 71.8 5.0 71.8 5.0 72.1 4.9
Age 75, % 30.2 30.4 30.1 30.4 30.1 30.6 30.7
Male, % 48.9 49.5 48.2 48.5 48.0 62.0

50.1
Systolic BP 168 13 167 13 168 13 167 13 168 12 169 13 172 14
Diastolic BP 91 8 91 8 91 8 91 8 91 8 89 9 88 9
BMI 27 4 27 4 27 4 27 4 27 4 28 4 28 4
Previous history
Antihypertensive therapy, % 62.2 62.0 62.4 60.9 62.0 75.1 67.9
Preexisting diabetes, % 7.2 7.5 7.0 — — 100 100
Coronary heart disease, % 7.9 7.8 8.0 7.7 7.8 9.6 9.9
Cerebrovascular disease, % 4.5 4.6 4.4 4.7 4.2 4.4 7.5
Raised cholesterol, % 22.2 22.7 21.8 23.1 22.0 17.7 18.6
Current smoker, % 7.1 6.9 7.3 6.9 7.3 6.6 7.6
Increased plasma creatinine, % 11.9 11.8 12.0 11.6 12.1 14.4 10.4
High RBS, % 2.3 2.7

1.9 0.7 0.4 27.9 21.1
ACEI¼ angiotensin-converting enzyme inhibitor, BMI¼ basal metabolic index, BP¼ blood pressure, RBS¼ random blood sugar.
p ve
Medicine  Volume 94, Number 9, March 2015 Cost–Utility Analysis of Hypertension Treatment in Elderlymales.23 There were few significant differences in baseline
characteristics between the treatment groups, including
when comparing subgroups based on presence of diabetes at
baseline, except for a higher random blood sugar in the ACEI
group overall, and there were more males in the ACEI group
among patients with diabetes at baseline (Table 2). The
duration of diabetes in the preexisting diabetes group at the
commencement of the clinical trial was 9.4 years (median).

Significant differences (P< 0.05) for the comparison of ACEI grou
variables and x2 used for categorical variables.Overall, during a maximum follow-up period of 5 years
(median 4.1 year), the ANBP2 patients experienced 505 non-
fatal cardiovascular events (diuretic group 260 and ACE-I
TABLE 3. Results of the Cost-Effectiveness Analysis Simulated in







Group A, hypertensive patients free from diabetes at start
ACEI 77 49 66 4089 80
Diuretic 76 72 69 4069 78
Difference 19.5
Difference/subject 0.019
Group B, hypertensive patients with preexisting diabetes at start
ACEI 103 — 78 3467 1,0
Diuretic 198 — 116 3378 1,9
Difference 89.4
Difference/subject 0.089
ACEI¼ angiotensin-converting enzyme inhibitor, AUD¼Australian do
cost-effectiveness ratio, QALY¼ quality-adjusted life-year.
Costs are less and effectiveness is greater for ACEI-based treatment.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.group 245), 339 were newly diagnosed with diabetes (diuretic
group 200 and ACE-I group 139), and there were 396 deaths
(diuretic group 206 and ACE-I group 190). The number of
observed events for groups A and B by antihypertensive
treatment group is summarized in Supplementary Table 1,
http://links.lww.com/MD/A217.
rsus diuretics group. One-way analysis of variance used for continuousCost-Effectiveness
The results of the cost-effectiveness analyses are summar-
ized in Table 3. For group A, restricted to participants diabetes
1000 Participants at Start
atients (Discounted)









3,402 875,635 1,357,918 3,036,955
4,099 412,789 1,301,341 2,498,229
538,725 AUD 27,698
AUD 539
59,417 2,844,547 1,721,735 5,625,699
92,992 2,321,439 1,477,780 5,792,211
166,512 Dominant
AUD 167
llar, CV¼ cardiovascular, GP¼ family physician, ICER¼ incremental
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free at baseline, the overall net cost (discounted) was AUD 539
(s350) per person with 0.019 QALY gained (discounted) per
person. The ICER for ACEI-based treatment compared with
thiazide-based treatment was AUD 27,698 (s18,004) per
QALY gained. For group B, restricted to participants with
preexisting diabetes at baseline, ACEI-based treatment was a
dominant strategy, being both more effective and less expensive
than thiazide diuretic-based (mainly hydrochlorothiazide) treat-
ment during the trial period. Here, there was an overall net
saving (discounted) of AUD 167 (s109) per person with 0.089
QALY (discounted) gained per person (Table 3). Detailed
information on the QALYs gained and costs for the ACEI-
Chowdhury et albased and diuretic-based treatment by year for group A and
group B cost-effectiveness analysis is summarized in Supple-
mentary Table 2, http://links.lww.com/MD/A217.
TABLE 4. One-Way Sensitivity Analyses for ICER per QALY
Description of Inputs Value
Base case —
Sensitivity analysis—changing only 1 parameter
Health utilities
Preexisting diabetes
Lower limit of range 0.80
Upper limit of range 0.95
Nonfatal myocardial infarction
Lower limit of range 0.50
Upper limit of range 0.87
Nonfatal stroke
Lower limit of range 0.26
Upper limit of range 0.92
Nonfatal heart failure hospitalization
Lower limit of range 0.430
Upper limit of range 0.840
New-onset diabetes
Lower limit of range 0.60
Upper limit of range 0.98
Costs
Nonfatal MI
Cost reduced by 20% 6542
Cost increased by 20% 9813
Nonfatal stroke
Cost reduced by 20% 10,254
Cost increased by 20% 15,381
Nonfatal HF hospitalization
Cost reduced by 20% 6231
Cost increased by 20% 9346
Death (from any cause)
Cost reduced by 20% 1403
Cost increased by 20% 2104
Annual discount rate 3%
Sensitivity analysis—changing all utilities/cost parameters together
Health utilities
Lower limit of all utility range —
Upper limit of all utility range —
Costs
Lower limit of all cost range —
Upper limit of all cost range —
AUD¼Australian dollar, HF¼ heart failure, ICER¼ incremental cost-ef
life-year.
6 | www.md-journal.comSensitivity Analyses
The findings of the 1-way sensitivity analyses are presented
in Table 4. The results are sensitive to the utility value for new-
onset diabetes. In the probabilistic sensitivity analysis, the 95%
confidence interval for the ICER for group A ranged from AUD
13,769 (s8950) to AUD 101,557 (s66,012) and for group B from
AUD5239 (s3,405) (saving) to AUD 633(s411). The results
of the probabilistic sensitivity analysis are shown as cost-effec-
tiveness acceptability curves in Figure 2. Based on our assumed
cost-effectiveness threshold ICER value of AUD 50,000 per
QALY gained, for group A, there was an 85% probability that
Medicine  Volume 94, Number 9, March 2015use of ACEI compared with thiazide diuretic as a first-line
antihypertensive drug would be cost-effective. For group B,
use of ACEI-based treatment compared with diuretic-based
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FIGURE 2. Probabilistic sensitivity analysis presented as cost-
effectiveness acceptability curves per QALY gained by ACEI-based
treatment versus diuretic-based treatment. ACEI¼ angiotensin-
Medicine  Volume 94, Number 9, March 2015treatment was always cost-effective, and there was an 86%
probability that it would be a ‘‘dominant’’ strategy. The sensi-
tivity analysis disregarding both preexisting and new-onset dia-
betes and the costs of diabetes management during follow-up
suggested an ICER of AUD 64,112 (s41,673) for the trial
participants overall for ACEI-based treatment compared with
thiazide-based treatments.
DISCUSSION
Our cost-effectiveness analyses from the Australian gov-
ernment’s perspective suggest that commencing antihyperten-
sive treatment with an ACEI (mainly enalapril) rather than a
thiazide diuretic (mainly hydrochlorothiazide) would be cost-
effective in the elderly who are free from diabetes at the
initiation of treatment, if an implicit threshold of AUD
50,000 per QALY gained is chosen. For elderly hypertensive
patients with preexisting diabetes, commencing treatment with
an ACEI rather than a thiazide diuretic would be a dominant
approach (ie, both more effective and cost saving).
Economic evaluations conducted in general populations
considering only cardiovascular events and mortality have
suggested that commencing antihypertensive treatment with
an ACEI is not cost-effective when compared with commencing
treatment with a thiazide diuretic.15,21 These previous studies
were not undertaken in relation to an elderly population and did
not consider new onset of diabetes as an outcome of antihy-
pertensive treatment. The results of our study have demon-
strated the importance of considering the impact of the
important comorbidity of diabetes on the management of
elderly hypertensive patients. This is illustrated by our sensi-
tivity analysis disregarding both preexisting and new-onset
diabetes and the costs of diabetes management during fol-
low-up being in line with earlier findings suggesting ACEI
not to be cost-effective compared with thiazide diuretics as a
converting enzyme inhibitor, AUD¼Australian dollar, ICER¼
incremental cost-effectiveness ratio, QALY¼quality-adjusted
life-year.first-line antihypertensive drugs despite our base case results
indicating the opposite. Current practice guidelines for the
management of hypertension recommend the use of a thiazide
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.diuretic, an ACEI, an angiotensin receptor antagonist, or a
calcium channel antagonist in the elderly as the preferred
first-line drug in the absence of comorbidities.13,14 These
clinical guidelines have mostly been based on clinical trial
findings; however, there is some less robust evidence for better
effectiveness of ACEI compared with diuretics as first-line
antihypertensive drugs.37 Moreover, only a limited number
of studies have been undertaken on the elderly comparing
the outcome of treatment with ACEI and diuretics, and then
analyzing the cost-effectiveness of these treatments. A study
using a health economic model in a 65-year-old population with
an annual diabetes risk of 1.1% showed that a calcium channel
antagonist is the most cost-effective initial drug for high BP.16
This study reported a minimal absolute difference between
calcium channel antagonists and ACEI. The available cost-
effectiveness analyses for ACEI compared with placebo con-
ducted in high risk hypertensive patients show that the use of
ACEI is a cost-effective approach.38,39
The global cardiovascular disease burden is increasing
over time, and hypertension is an important risk factor.40
Previous findings have demonstrated the beneficial effects of
ACEI on reducing cardiovascular events, as well as a lowered
incidence of new-onset diabetes,17–20,41 and suggest that,
despite the higher dispensed price of ACEI-based treatment,
it will become cost-effective once the trade-off between health
outcomes and resource costs is considered. Our findings
confirm that, despite the higher dispensed price, ACEI-based
treatment will be more cost-effective compared with diuretics in
treating elderly hypertensive patients when new-onset diabetes
is considered. Some of the previous studies suggested that
switching from diuretics to another antihypertensive drug once
diabetes has developed can be a cost-effective approach. How-
ever, conclusions derived from these studies may be contro-
versial, because once diabetes develops it can give rise to many
complications along with an increased risk of mortality in the
long term.20,42
The cost-effectiveness analyses that we have used had
several limitations. Firstly, we did not incorporate treatment
adherence in the analysis, because we had only limited infor-
mation on this. However, in a subanalysis using the limited data
available, we did not observe any differences in treatment
adherence between the ACEI and thiazide diuretic-based treat-
ment groups. Moreover, we observed that about 58% and 62%
of the participants remained in their assigned ACEI and diuretic
groups, respectively, at the end of the ANBP2 study. In com-
parison, among those who developed diabetes during the trial
period, 63% and 61% of remained in their assigned ACEI and
diuretic groups, respectively. This suggests that there was little
contamination bias. Secondly, we did not consider any add-on
drug cost in the analysis, and we made the assumption that the
add-on drug costs were similar in both treatment groups. At the
end of the study, the add-on drugs in both the treatment group
participants were similar: the number of participants on mono-
therapy in the ACEI group was 65% and in the diuretic group
was 67%, whereas 6% in the ACEI group and 5% in the diuretic
group were on 3 or more antihypertensive agents.23 Third, other
cardiovascular and noncardiovascular events that might have
affected the cost-effectiveness were not considered in these
analyses. For example, chronic kidney disease is one of the
common health problems in hypertensive patients other than
diabetes, and available literature suggests that ACEI-based
Cost–Utility Analysis of Hypertension Treatment in Elderlytreatment may be better in preserving kidney function.43,44
Inclusion of such a condition may favor initiating treatment
with an ACEI even more. Fourthly, we did not consider any
www.md-journal.com | 7
specialist consultations, by either medical or allied health
professionals, although for instance such costs might have
been incurred in relation to the management of diabetes. We
also did not consider any posthospitalization cost such as for
rehabilitation following nonfatal cardiovascular events.
Finally, our cost-effectiveness analysis has been conducted
from the Australian health care perspective using predomi-
nantly white participants. Therefore, our findings may only be
generalizable to countries with similar health care systems and
racial backgrounds. However, ANBP2 was a pragmatic ‘‘real-
world’’ study performed on a large number of elderly hyper-
tensive people, and used information from actual observed
events. Therefore, the identified findings will be relevant when
treating physicians make treatment decisions on a day-to-
day basis.
In conclusion, the use of ACEI-based treatment as a first-
line antihypertensive drug for those aged 65 years or older
instead of thiazide diuretic-based (mainly hydrochlorothiazide)
treatment appears to be a cost-effective strategy for the pre-
vention of adverse cardiovascular outcomes when diabetes is
present or subsequent on-treatment development of diabetes
is considered.
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